Hepatitis C Virus (HCV) infection is the commonest viral infection affecting hemodialysis patients. Higher mortality and morbidity rates are reported in theses patients. In addition progression of liver disease after kidney transplantation is enhanced in these patients leading to higher mortality and morbidity. The only available treatment is interferon monotherapy while on dialysis. Large size studies that assess the effectiveness and tolerability of interferon in these patients are lacking. The aim of this meta-analysis is to summarize the sustained viral response and assess the response to treatment by duration of therapy and viral genotype.We searched MEDLINE and EMBASE databases. The search was limited to studies that included more than 10 dialysis patients and had adequate descriptions of the needed information. 25 studies met the inclusion criteria. The studies included 557 patients on dialysis treated with interferon. Studies included both gender and had acute and chronic HCV infected patients. The commonest reason for patient selection in the studies was transplant preparation. 59.0% (95% CI 55.2-62.8) achieved End of Treatment Reponses and 40.0% (95% CI 36.0-44.0%) had sustained viral response six months after stopping the therapy. The commonest reason for discontinuation was generalized fatigue and asthenia state in 31(35.6%). Secondary analysis found no difference in response rate between different treatment durations, acuteness of the infection and viral genotype. HCV genotype 1 was the commonest genotype found accounting for 74% of the tested patients. interferon monotherapy in dialysis patients has very good sustained viral response but with high rate of adverse events. Interferon therapy should be offered to dialysis patients with HCV infection. The optimal dose and duration of the treatment should be tested in future randomized control trial.